By Nick Paul Taylor
Pfizer and BioNTech have shared (PDF) phase 1/2 data suggesting their COVID-19 vaccine triggers stronger CD8 T-cell responses than Moderna’s rival candidate. Four-fifths of subjects who received BNT162b1 had vaccine-induced CD8 T-cell responses and researchers classed most of the responses as strong.
read more
By Conor Hale
The FDA authorized its first COVID-19 diagnostic test for use with pools of samples in a move to let laboratories conserve resources by evaluating groups of people at once.
read more
By Heather Landi
Ridesharing giant Uber has rolled out a service to give public health officials quick access to user data to track coronavirus cases, Reuters reported. Find out how data about Uber's services could help with efforts to curb the pandemic.
read more
By Kyle Blankenship
Western intelligence officials pegged Russian hackers with an attempt to rip off leading research for a COVID-19 vaccine. Russia has denied involvement in any attacks and with a new licensing deal for AstraZeneca's COVID-19 shot, the country says it doesn't need the secrets anyway.
read more
By Arlene Weintraub
SARS-CoV-2, the virus that causes COVID-19, binds tightly to heparin, which is widely used to treat and prevent blood clots, scientists at Rensselaer Polytechnic Institute discovered. An inhaled form of the drug could be used as a decoy to prevent the virus from invading healthy cells, they proposed.
read more
By Tina Reed
The Department of Health and Human Services plans to begin distributing $10 billion in additional relief funds to hospitals in areas hit hard by the COVID-19 pandemic.
read more
By Kyle Blankenship
Pfizer and BioNTech have the ball rolling on their mRNA-based COVID-19 vaccine candidates with late-stage human testing set to begin later this month. And as they barrel toward a potential regulatory review, the partners are starting to cut deals with national buyers.
read more
By Ben Adams
A U.K. biotech has seen its shares skyrocket on new data from its experimental treatment in hospitalized COVID-19 patients, but it’s too early for game-changer cliches.
read more
By Healthcare Staff
Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
Russia is using a newly-unveiled vaccine supply deal with AstraZeneca to fend off claims that a government-affiliated hacker group tried to steal Western COVID-19 research. China's CanSino released phase 2 data on its vaccine hopeful. The U.K. tapped small vaccine maker Valneva for up to 100 million future doses.
read more
By Paige Minemyer
Many employers are in the midst of transitioning their workplaces to the COVID-19 reality, and they’re leaning on health insurers to assist with the process, according to a new survey from Optum.
read more
By Conor Hale
Without a doubt, the COVID-19 pandemic has shifted the landscape for medtech companies over the past several months, and Philips’ second-quarter earnings report illustrates those changes in stark relief.
read more
By Eric Sagonowsky
COVID-19 frontrunners have been inking deals to supply vaccines if their programs succeed, and now Valneva is getting involved. The company reached an agreement in principle with the U.K. government to supply up to 100 million doses of its vaccine candidate, which will be produced in Scotland.
read more
